NL-OMON44210
已完成
不适用
A single-arm, observational study to explore and characterize wound healing after skin punch biopsies in healthy volunteers - Wound healing in healthy volunteers
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Wound healing
- 发起方
- Centre for Human Drug Research
- 入组人数
- 18
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Eligible subjects must meet all of the following inclusion criteria at screening:
- •1\. Healthy subjects, 18 to 30 years of age (inclusive). The health status is verified by absence of evidence of any clinical significant active or uncontrolled chronic disease following a detailed medical history, a complete physical examination including vital signs, blood sampling of hematology, chemistry, and virology, urinalysis, urine drug and cotinine testing, and alcohol breath testing. In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects.
- •2\. Body mass index (BMI) between 18 and 30 kg/m2, inclusive
- •3\. Fitzpatrick Skin type I\-II (Caucasian type).
- •4\. Eligible lower back to perform biopsies (no excessive hair growth, no local skin disorder)
- •5\. Willing to give written informed consent and willing and able to comply with the study protocol.
排除标准
- •Eligible subjects must meet none of the following exclusion criteria at screening:
- •1\. History of pathological scar formation (keloid, hypertrophic scars)
- •2\. Any form of body modification of the lower back hindering biopsy collection of unaltered skin (e.g. tattoos, piercings, implants)
- •3\. Any disease associated with immune system impairment, including auto\-immune diseases, HIV and transplantation patients.
- •4\. Requirement of immunosuppressive or immunomodulatory medication, including glucocorticoids, non\-steroid anti\-inflammatory drugs (NSAIDs), and chemotherapeutic drugs within 30 days prior to enrollment or planned to use during the course of the study.
- •5\. Have any current and / or recurrent pathologically, clinical significant relevant skin condition.
- •6\. Use of topical medication (prescription or over\-the\-counter (OTC)) within 30 days of the start of the study in local treatment area.
- •7\. Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding.
- •8\. Current smoker and/or regular user of other nicotine\-containing products (e.g., patches).
- •9\. Average consumption of more than 14 units of alcohol per week
结局指标
主要结局
未指定
相似试验
尚未招募
2 期
To study the effect of Vyaghradi Kashay tablet on COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/10/028570Ministry of AYUSH Govt of India
进行中（未招募）
不适用
An open, prospective, single-arm study investigating safety and efficacy of the human hepatitis B immunoglobulin BT088 after subcutaneous application in liver transplanted patientsClinical Phase: III - STUDY 974PROPHYLAXIS OF HEPATITIS B REINFECTION AFTER LIVER TRANSPLANTATIONMedDRA version: 9.1Level: LLTClassification code 10058827Term: Hepatitis B reactivationEUCTR2008-007625-39-ITBiotest AG130
进行中（未招募）
不适用
A clinical trial of Zutectra in patients who recently received a liver transplantEnsayo Clínico de Zutreca en pacientes que se han sometido a un trasplante de hígadoHepatitis B re-infecciónHepatitis B re-infectionMedDRA version: 14.1Level: LLTClassification code 10058827Term: Hepatitis B reactivationSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2012-002516-51-ESBiotest AG60
进行中（未招募）
不适用
A clinical trial of Zutectra in patients who recently received a livertransplantHepatitis B re-infectionMedDRA version: 15.0Level: LLTClassification code 10058827Term: Hepatitis B reactivationSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2012-002516-51-ITBIOTEST AG60
进行中（未招募）
1 期
A clinical trial of Zutectra in patients who recently received a liver transplantHepatitis B re-infectionMedDRA version: 20.1 Level: PT Classification code 10058827 Term: Hepatitis B reactivation System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2012-002516-51-GBBiotest AG60